Looks Health (534422)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looks Health is precisely the kind of cigar butt that fascinates bargain hunters: ₹5.73 per share against ₹15.02 book value, a 62% discount. But in Graham's world, a low price-to-book is only a starting point, not a conclusion. The hardest evidence is missing — latest quarter sales are ₹0 Cr and net profit is ₹0 Cr. A business that earns almost nothing on its assets is not a business; it is a balance sheet waiting for a catalyst. ROE of 1.38% and ROCE of 0.40% confirm that capital is sitting idle. The reported 133% profit growth and 49.57 P/E are statistical illusions, because the earnings base is negligible and the direction can reverse with one expense item. The Piotroski F-score of 6/9 suggests the company is not in immediate distress, but that score says little about future economics. No dividend, no sales growth, and promoter holding not disclosed leave an information vacuum. A P/B of 0.38 can be rewarding if book value is real — land, investments, receivables — and shareholders can force realization. It can also be a trap if the book is inflated or tied up in non-earning, illiquid assets. With market cap at ₹6 Cr, this is micro-cap territory where operating costs and one-off events swamp fundamentals. I cannot call it a wonderful business; therefore it is not a wonderful investment. It is an asset play, and only for those who can independently verify the assets and the intentions of control holders. I will watch, not buy, until evidence of value-unlocking appears.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer